Stifel Nicolaus Keeps Their Hold Rating on BioMarin Pharmaceutical (BMRN)

Stifel Nicolaus analyst Paul Matteis maintained a Hold rating on BioMarin Pharmaceutical on December 11. The company’s shares closed last Friday...

Read Full Article →